Biomerica Announces Medicare Pathway

Biomerica has received confirmation from a Medicare Administrative Contractor for individual claim reviews of its inFoods IBS product. This development signifies a crucial step towards establishing a scalable commercialization pathway within the Medicare program. The company and its laboratory partner believe that properly documented claims are well-positioned for reimbursement under the existing $300 CMS rate. This confirmation is a significant milestone, potentially unlocking substantial revenue streams and expanding access to their diagnostic solutions for Medicare beneficiaries.